Cystic Kidney Disease: Clinical Diagnosis, Treatment and Outcomes
A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Nephrology & Urology".
Deadline for manuscript submissions: closed (20 November 2022) | Viewed by 17035
Special Issue Editor
Interests: prostate cancer; robotic surgery; genetics; digital therapeutics; testosterone
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disease, with 12 million patients globally. PKD1 and 2 have been identified as the genes responsible for ADPKD. About half of ADPKD patients require kidney replacement therapy (KRT) by the age of 70. Patients have anxiety concerning the inherited effects on their families and the need for KRT.
Tolvaptan, a V2 receptor inhibitor, has been clinically shown to slow the growth of cysts and reduce renal damage. The introduction of tolvaptan dramatically changed the landscape of ADPKD treatment. Recent cellular research has highlighted a potential role for cellular metabolic changes in the pathogenesis of ADPKD. Additionally, new therapeutic approaches are now ongoing as clinical trials.
This Special Issue provides basic and clinical insights into ADPKD, for which a second paradigm shift is just around the corner.
Prof. Dr. Shigeo Horie
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- ADPKD
- polycystin
- tolvaptan
- TKV, WGS
- mitochondria, oxidative stress
- inflammation